Pharmaceutics (Journal)

Activity: Publication peer-review/editorial workEditor/reviewer for publications (incl. CDCF T61 Journal Editor)


Topic Information
Dear Colleagues,

Alzheimer’s disease (AD) is an age-associated neurodegenerative disease (ND) affecting social and behavioral activities. Prevalent studies indicate that the global AD population will reach 114 million by 2050. Presently, AD remains incurable, and the high failure rate of clinical trials for AD-related drugs has raised the need to understand the molecular mechanisms of AD. In addition, there is an utmost need to develop novel drugs as therapeutics and theranostic approaches for the early detection of AD progression and to target the molecular-level brain delivery of small molecules using nanocapsules as therapeutics for AD. Using advanced technology for the treatment of AD in diagnostics, brain delivery, and therapeutics will result in a bench-to-bedside solution in AD therapy. The application of advanced technology in drug discovery, diagnostics, and brain delivery systems has been flourishing in recent years for the remedy of Alzheimer’s disease. Inter-disciplinary approaches and strategies have helped understand the prognosis and pathogenesis of Alzheimer’s disease (AD). Unfortunately, there are no single confirmatory tests or diagnostics that can clinically be used to identify and determine the presence or absence of Alzheimer’s pathology. Therefore, AD has posed tremendous challenges for researchers in the scientific community and medical experts to tackle the unresolved issues in early detection, diagnostics, and therapeutics for AD.

Dr. Ashok Iyaswamy
Dr. Chuanbin Yang
Dr. Abhimanyu Thakur
Topic Editors
Period11 Jun 2025
Type of journalJournal
Degree of RecognitionInternational

User-Defined Keywords

  • diagnostic probes
  • therapeutic agents
  • autophagy inducers
  • exosomes
  • Alzheimer’s disease